Laboratory Evaluation and Ancillary Testing Guide

Course Overview

Laboratory evaluation in Testosteronology® must answer a specific clinical question. If the clinician does not define that question first, the laboratory results will create noise rather than clarity. The most important first step is identifying whether the patient is untreated, already on testosterone therapy, or currently or previously exposed to anabolic-androgenic steroids or other exogenous androgens. That single distinction determines whether the clinician is diagnosing hypogonadism, localizing dysfunction, monitoring therapy, or identifying complications that may be developing silently. Established endocrine and urologic guidance reinforces this approach by requiring symptom correlation, repeat morning testosterone confirmation for diagnosis, and structured monitoring once therapy begins.[1,2]

This course emphasizes that testosterone is only one data point inside a broader physiologic system. Hematologic risk, cardiometabolic status, renal function, fertility, prostate health, blood pressure, and sleep all interact with androgen biology. The clinician’s responsibility is to interpret laboratory data in the context of exposure, timing, symptoms, and system-wide health rather than relying on a single hormone value. This is the difference between prescribing testosterone and practicing Testosteronology®.

Learning Objectives

After completing this course, clinicians should be able to:

➀ Distinguish the laboratory goals for endogenous hypogonadism evaluation, testosterone monitoring, and anabolic steroid or other high-dose androgen exposure.

➁ Interpret core hormone testing including total testosterone, free testosterone, SHBG, LH, FSH, prolactin, and estradiol.

➂ Apply structured monitoring strategies for men on testosterone therapy using hematologic, metabolic, renal, and cardiovascular markers.

➃ Integrate ABCDS™ principles into laboratory interpretation and risk assessment.

➄ Select ancillary testing appropriately based on clinical indication rather than routine ordering.

Course Topics

The following topics will be covered in the course text, video, diagrams or downloadable documents:

➀ Core Principle: What the Laboratory Evaluation Must Answer

➁ Foundational Hormone Panel

➂ Men Not on Testosterone

➃ Men on Testosterone Therapy

➄ AAS / High-Dose Testosterone Exposure

➅ ABCDS™-Based Primary Care Laboratory Framework

➆ Ancillary Testing: Indications and Use

➇ Special Populations

➈ Clinical Integration

➉ Risk-Based STI Laboratory Evaluation

Video Lesson Takeaways

◉ Laboratory evaluation is a decision system, not a routine panel.

◉ Exposure state determines interpretation.

◉ Untreated patients require diagnosis and localization; treated patients require monitoring and risk surveillance.

◉ Total testosterone alone is often insufficient without SHBG context.

◉ LH and FSH are most useful before suppression.

◉ CBC must be interpreted alongside iron studies when erythrocytosis or phlebotomy is present.

◉ ABCDS™ monitoring prevents hormone tunnel vision.

◉ Ancillary testing should be ordered only when it changes management.

◉ Polypharmacy distorts standard interpretation patterns.

◉ Laboratory interpretation begins with history and timing, not the order set.

➀ Core Principle: What the Laboratory Evaluation Must Answer

The laboratory evaluation must begin with category recognition. In an untreated man, the laboratory task is diagnostic. The clinician is attempting to confirm biochemical hypogonadism and determine whether the pattern is primary or secondary. In a man already on testosterone therapy, the laboratory task shifts away from diagnosis and toward monitoring, because exogenous therapy changes gonadotropin physiology and alters the meaning of the hormone panel. In a man with anabolic steroid or high-dose androgen exposure, the laboratory task becomes broader still because suppression, cycling, stacking, recovery attempts, and concurrent drug use can distort the axis and create risk across multiple organ systems.[1,2]

The workup may be intended to confirm hypogonadism, localize etiology, monitor therapy, detect treatment complications, evaluate fertility risk, or identify broader medical harm. When that purpose is unclear, the laboratory results often create false confidence rather than clarity. One of the most important teaching points in this lesson is that the same testosterone value can mean very different things depending on the patient’s exposure state, timing, and clinical context. That is not a minor nuance. It is the difference between responsible androgen medicine and superficial prescribing.

A careful history and physical examination remain essential even in a laboratory-focused course like this one. Exposure history, timing of last dose, formulation, prior cycling, symptom pattern, sleep quality, comorbid disease, fertility goals, and concomitant agents all shape how the numbers should be interpreted. If the clinician does not know whether the patient is untreated, treated, suppressed, or recovering, even a technically accurate lab value can be clinically misleading.

➁ Foundational Hormone Panel

The foundational hormone panel includes total testosterone, free testosterone when indicated, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), albumin, prolactin, and ultrasensitive estradiol. Testosterone measurement should ideally use high-quality assays such as liquid chromatography–mass spectrometry because inaccurate laboratory methods can distort interpretation of total and free testosterone. In the untreated diagnostic setting, both the Endocrine Society and the AUA recommend making the diagnosis of testosterone deficiency only in men with consistent symptoms and unequivocally low testosterone concentrations confirmed on repeat morning testing using reliable assays.[1,2] Total testosterone therefore remains the anchor of the workup, but it should never be treated as a complete clinical answer.

Free testosterone becomes especially important when SHBG is abnormal, when total testosterone is borderline, or when the symptom picture does not align well with the total testosterone concentration. This is one of the most common real-world areas of confusion in testosterone medicine. A man can present with symptoms that strongly suggest androgen deficiency while carrying a total testosterone value that seems acceptable on paper. In those cases, the clinician should slow down and ask whether SHBG, metabolic disease, thyroid issues, liver disease, obesity, aging, or other binding-related factors may be altering the biologically available fraction in a clinically meaningful way.[1,2] Interpreting total testosterone without regard for binding dynamics is one of the easiest ways to miss an important clinical pattern.

LH and FSH are central to localization only when the patient is not suppressed by exogenous androgens. Elevated gonadotropins in the setting of low testosterone support primary hypogonadism, whereas low or inappropriately normal gonadotropins suggest secondary hypogonadism. Prolactin becomes particularly important when the pattern appears secondary because hyperprolactinemia can suppress the axis and may indicate pituitary pathology. Estradiol should be measured selectively, not reflexively, and when it is measured in men, ultrasensitive methodology is preferred because less specific assays can be misleading.[1,2]

➂ Men Not on Testosterone

In the untreated endogenous evaluation, diagnosis requires symptoms plus low testosterone on two properly obtained measurements. Clinicians should be cautious about drawing conclusions from a single value obtained under suboptimal conditions. Acute illness, poor sleep, caloric restriction, alcohol use, medication effects, and other transient variables can distort the picture. The purpose of repeat testing is to reduce the risk of labeling a reversible or situational abnormality as permanent hypogonadism. Additionally, identifying where the dysregulation is located along the HPG axis is important in testosterone naive patients.[1,2]

Fertility should be addressed before testosterone is started rather than after the HPG axis has already been altered by treatment. Men with present or future fertility goals should be asked directly about that goal up front, and semen analysis should be obtained when clinically indicated. Current male infertility guidance also supports selected genetic testing, including karyotype and Y-chromosome microdeletion analysis, in appropriately severe infertility patterns.[3]

Not every symptomatic man with a borderline testosterone value has true hypogonadism. Advanced clinical care often means resisting the urge to force a premature conclusion and instead repeating key studies correctly, identifying reversible contributors, and letting the pattern declare itself.

➃ Men on Testosterone Therapy

Once a man is on testosterone therapy, total testosterone remains important, but only when interpreted in relation to formulation, route, frequency, and timing from the last dose. Testosterone levels must always be interpreted relative to the timing of the most recent dose because peak and trough levels vary substantially depending on formulation and dosing interval. A value obtained near a post-injection peak answers a different question than one obtained near a trough. A transdermal preparation creates a different interpretive pattern than an injectable formulation. Pellets create another. One of the easiest ways to make poor clinical decisions is to interpret a testosterone value without knowing when the sample was drawn relative to the formulation being used.

The core monitoring set in this group includes testosterone, CBC with attention to hematocrit, PSA, CMP, lipid panel, hemoglobin A1C, and blood pressure tracking using ambulatory blood pressure monitoring (ABPM). ABPM logs often provide more clinically useful information than isolated office measurements when evaluating cardiometabolic risk in men receiving androgen therapy. Estradiol may be added when symptoms or treatment questions justify it, but it is not presented here as a mandatory routine anchor in every stable follow-up panel. That emphasis is consistent with major guidelines, which focus on structured monitoring for therapeutic response, adverse effects, and overall safety rather than indiscriminate hormone ordering.[1,2]

A particularly important threshold is hematocrit. The AUA guideline states that while on testosterone therapy, a hematocrit of 54% or greater warrants intervention.[2] Androgen induced erythrocytosis is often clinically silent until risk becomes more significant. The clinician’s job is to detect that trend before it becomes more dangerous. Repeated therapeutic phlebotomy used to manage erythrocytosis can produce iron depletion, so iron studies should be evaluated alongside hematologic monitoring when phlebotomy is used.

Another key teaching point in this section is that LH and FSH are generally not useful once a patient is established on exogenous testosterone. Suppressed gonadotropins in that setting do not localize disease in the same way they do during untreated evaluation.

➄ AAS / High-Dose Testosterone Exposure

Men with anabolic-androgenic steroid exposure or high-dose testosterone use require a broader and more skeptical laboratory framework than men on standard TRT alone. In this population, hormone values are shaped by timing from last exposure, recovery phase, cycling pattern, stacking, and concurrent agents. Total testosterone, free testosterone, SHBG, estradiol, prolactin, and selected LH/FSH testing may all be relevant, but the interpretation depends heavily on whether the patient is actively suppressed, recently discontinued, partially recovering, or using so-called post-cycle agents that alter the picture without fully restoring normal physiology.

This group also requires more extensive complication surveillance. CBC is essential because erythrocytosis is common. CMP, cystatin C, urinalysis, urine albumin-creatinine ratio, iron studies, lipids, ApoB, Lp(a), A1C, PSA, and semen analysis may all be relevant depending on the duration, intensity, and pattern of exposure.

The cardiovascular dimension is especially important. Long-term supraphysiologic anabolic steroid exposure has been associated with hypertension, dyslipidemia, fibrosis, arrhythmias, myocardial dysfunction, and cardiomyopathy.[4] Not every exposed patient needs advanced cardiac imaging, but the threshold for broader cardiovascular assessment should be lower when exposure is prolonged, symptoms are present, exercise tolerance has changed, or other risk markers are abnormal. Fertility deserves special attention because prolonged suppression and repeated cycling can create reproductive consequences that are not visible from testosterone alone. “Recovery” should not be defined by a single improved hormone value. A patient may look improved on paper while fertility remains impaired, blood pressure remains elevated, or cardiac and renal risk markers remain unfavorable. [3]

Finally, polypharmacy is one of the most important pieces of the puzzle. Many IPED users are not using testosterone alone. Growth hormone, peptides, SERMs, aromatase inhibitors, diuretics, stimulants, thyroid agents, and other compounds can all change symptoms, laboratory results, and clinical risk. A careful and nonjudgmental exposure history is therefore essential. Without it, the lab interpretation will almost always be incomplete.

➅ ABCDS™-Based Primary Care Laboratory Framework

The ABCDS™ framework is what keeps testosterone medicine connected to internal medicine. The core medical laboratory set described in this course can apply to most patients. Not every patient requires every possible test at every visit. Clinical decisions should be evaluated across glycemic, cardiovascular, renal, hematologic, and structural domains rather than reduced to a narrow hormone-focused model. [1,2]

A patient can improve symptomatically while worsening in ABCDS™ domains. Hematocrit can rise, blood pressure can drift, glycemic control can worsen, ApoB can remain unfavorable, renal stress markers can emerge, and sleep-disordered breathing can persist while the patient reports feeling “great.” Clinical improvement does not eliminate the need for objective monitoring.

➆ Ancillary Testing: Indications and Use

Ancillary testing should be targeted rather than routine. Pituitary MRI becomes appropriate in secondary hypogonadism, elevated prolactin, severe testosterone deficiency, infertility, concerning endocrine features, or central nervous system symptoms. Earlier evidence suggests that the yield of pituitary imaging is meaningfully higher when the endocrine pattern is suspicious than when MRI is ordered indiscriminately in all hypogonadal men.[5]

Cardiovascular imaging also requires judgment. Echocardiography may be appropriate in patients with cardiac symptoms, suspected cardiomyopathy, or prolonged anabolic steroid exposure. Coronary artery calcium scoring can aid risk stratification in moderate- or higher-risk men, while CT coronary angiography is more naturally used in symptomatic or otherwise higher-risk presentations when the question is active coronary evaluation rather than general screening. Electrocardiography may be obtained as a baseline or for symptom-driven assessment.

Sleep study referral should be considered when erythrocytosis persists despite appropriate management or when clinical features suggest obstructive sleep apnea (OSA). Published data have associated polycythemia in hypogonadal men on TRT with a higher prevalence of OSA.[6] Similarly, DEXA scanning becomes more relevant in severe hypogonadism, fracture risk, or long-term suppression. Testicular ultrasound should be obtained when physical examination or symptoms suggest a possible structural abnormality such as a mass or malignancy. Ancillary testing expands the workup only when the history, physical examination, or lab pattern gives the clinician a clear reason to do so.

➇ Special Populations

Klinefelter syndrome should be considered in men with low testosterone, elevated LH and FSH, small testes, infertility, or a suggestive clinical pattern. Confirmation is made with karyotype testing, and fertility counseling should be integrated early because reproductive decision-making is often time-sensitive.[3]

Kallmann syndrome and other forms of congenital hypogonadotropic hypogonadism should be considered in men with low testosterone, low or inappropriately normal LH and FSH, delayed puberty, anosmia, or a compatible family history. In such patients, MRI and genetic evaluation may be appropriate because the diagnostic frame is different from acquired adult-onset testosterone deficiency. Patients with broader pituitary or central nervous system disorders may also require a full pituitary hormone panel when multihormonal deficiency is suspected.[1,5]

The clinician should pause and reconsider whether a syndromic or central process is present when the following characteristics present in a patient:

Unusual phenotype
Striking reproductive history
Gonadotropin pattern not fitting expectations
Presentation out of proportion to common clinic patterns

That willingness to slow down is one of the markers of mature clinical judgment.

➈ Clinical Integration

The integrated-care theme is especially important in testosterone practice because androgen-related treatment intersects directly with primary care. Cardiovascular prevention, diabetes screening, kidney surveillance, prostate health, sleep medicine, fertility, and sexual health remain part of the clinician’s responsibility even when the patient initially presents for testosterone, libido, energy, or performance concerns. Routine preventive screening opportunities such as colorectal cancer screening may also arise during laboratory evaluation when age-appropriate.[1-3]

➉ Risk-Based STI Laboratory Evaluation

Risk-based STI evaluation should follow a focused sexual history rather than universal indiscriminate panel ordering. Current CDC recommendations support HIV screening at least once for all individuals aged 13 to 64, with repeat testing based on risk, and they support risk-based, exposure-site-specific screening for syphilis, gonorrhea, and chlamydia. Hepatitis B screening and vaccination review, hepatitis C screening with repeat testing when risk persists, selective HSV testing, and trichomonas testing when clinically indicated fit that same logic.[7] A patient presenting for testosterone, fertility, libido, or performance concerns may still warrant ordinary STI-related diligence. Risk-based and site-specific testing is more defensible than routine universal panels that ignore the actual history.

REFERENCES

Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
Brannigan RE, Sandlow JI, Schlegel PN, et al. Updates to male infertility: AUA/ASRM guideline. J Urol. 2024;212(2):244-253.
Fadah K, Gopi G, Lingireddy A, Blumer V, Dewald T, Mentz RJ. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023;10:1214374.
Rhoden EL, Estrada C, Levine L, Morgentaler A. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol. 2003;170(3):795-798.
Lundy SD, Parekh NV, Shoskes DA. Obstructive sleep apnea is associated with polycythemia in hypogonadal men on testosterone replacement therapy. J Sex Med. 2020;17(7):1297-1303.
Centers for Disease Control and Prevention. STI screening recommendations. CDC. Updated July 22, 2021. Accessed March 29, 2026. https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm

Laboratory Evaluation and Ancillary Testing

Course Overview

Learning Objectives

Course Topics

006 Laboratory Evaluation and Ancillary Testing

Video Lesson Takeaways

➀ Core Principle: What the Laboratory Evaluation Must Answer

➁ Foundational Hormone Panel

➂ Men Not on Testosterone

➃ Men on Testosterone Therapy

➄ AAS / High-Dose Testosterone Exposure

➅ ABCDS™-Based Primary Care Laboratory Framework

➆ Ancillary Testing: Indications and Use

➇ Special Populations

➈ Clinical Integration

➉ Risk-Based STI Laboratory Evaluation

Recommended Grand Rounds Case Reviews

Advanced Clinical Training Insights